GX E2

Drug Profile

GX E2

Alternative Names: EPO-hFC; EPO-hybrid Fc; EPO-hyFc; Erythropoietin biobetter - Genexine; GC-1113; GXE2; Long-acting EPO; Recombinant erythropoietin long-acting - Genexine/GC Pharma

Latest Information Update: 07 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genexine
  • Class Antianaemics; Biobetters; Recombinant erythropoietins; Recombinant fusion proteins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Anaemia

Most Recent Events

  • 20 Apr 2017 Genexine completes a phase II trial in Anaemia in South Korea (IV, SC) (NCT02044653)
  • 25 Feb 2016 Phase-II development is ongoing in South Korea
  • 16 Feb 2016 GX E2 licensed to Shanghai ChemoWanbang Biopharma in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top